Company: PETVW
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001493152-25-011967
Chunk: 41

Company: PetVivo Holdings, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 41
---
.
The decrease is primarily due to decreased general and administrative (“G&A”) expenses and research and development (“R&D”)
expenses.

27

General
and administrative (“G&A”) expenses were $1,068,818 and $1,233,261 for the three months ended June 30, 2025 and 2024,
respectively. General and administrative expenses include compensation and benefits, contracted services, legal and consulting fees,
and stock compensation expenses.

Sales
and marketing expenses were $621,712 and $534,413 for the three months ended June 30, 2025 and 2024, respectively. Sales and marketing
expenses include compensation, consulting, tradeshows, and stock compensation costs to support the launch of our Spryng®
product.

Research
and development (“R&D”) expenses were $340,513 and $387,515 for the three months ended June 30, 2025 and 2024, respectively.
The decrease was primarily related to decreased clinical studies due to tight cash flow constraints.

Operating
Loss. As a result of the foregoing, our operating loss was $1,844,317 and $2,044,432 for the three months ended June 30, 2025
and 2024, respectively. The decrease was related to cost-cutting initiatives in general and administrative and research and development
expenses.

Other
Income (Expense). Other income (expense) was ($466,720) for the three months ended June 30, 2025 compared to other expense of
($2,631) for the three months ended June 30, 2024. Other income (expense) in 2025 consisted of unrealized loss on change in derivative
liabilities and loss on disposal of assets. Other income (expense) in 2024 consisted of interest expense.

Net
Loss. Our net loss for the three months ended June 30, 2025 was $2,311,037 or ($0.09) per share as compared to a net loss of
$2,047,063 or ($0.11) per share for the three months ended June 30, 2024. The increase was primarily related to the loss on change in
derivative liabilities and the loss on disposal of assets. The weighted average number of shares outstanding was 24,302,790 compared
to 18,683,975 for the three months ended June 30, 2025 and 2024, respectively.

LIQU